Occam is pleased to announce that Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, has appointed Rabia Gurses Ozden, M.D. to its Board of Directors.
Rabia currently serves as the Senior Vice President of Clinical Development at Ocular Therapeutix, a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye. Prior to joining Ocular Therapeutix, Rabia served as the Chief Development Officer at Akouos, leveraging their adeno-associated virus (AAV)-based gene therapy platform to advance precision therapies for forms of sensorineural hearing loss. Prior to joining Akouos, Rabia served as the Chief Medical Officer at Nightstar Therapeutics, an ocular gene therapy company focused on AAV treatments for inherited retinal diseases, which was acquired by Biogen in 2019. Additionally, Rabia has held leadership positions at Applied Genetic Technologies and GlaxoSmithKline, while spending her early career in clinical development roles. Rabia earned her M.D. from Hacettepe University School of Medicine, completed her ophthalmology residency at Ankara University School of Medicine, and her clinical fellowship in Glaucoma at the New York Eye and Ear Infirmary.